Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.46 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2306490 | 1.00 | PTPN1 (0.52) | PTPN1SCN9AALDH1A1MAPTATM | |
| SCHEMBL2306572 | 0.82 | ITGB3 (0.48) | PTPN1ALDH1A1P2RX3ITGB3ITGA2B | |
| SCHEMBL2310144 | 0.82 | ITGB3 (0.48) | PTPN1ALDH1A1MAPTP2RX3ITGB3 | |
| SCHEMBL2310496 | 0.82 | ITGB3 (0.48) | PTPN1ALDH1A1ITGB3ITGA2BALPI | |
| SCHEMBL2310489 | 0.82 | ITGB3 (0.48) | PTPN1ALDH1A1ITGB3ITGA2BALPI | |
| SCHEMBL2310136 | 0.82 | ITGB3 (0.48) | PTPN1ALDH1A1MAPTP2RX3ITGB3 | |
| SCHEMBL2306563 | 0.82 | ITGB3 (0.48) | PTPN1ALDH1A1P2RX3ITGB3ITGA2B | |
| SCHEMBL21803821 | 0.79 | GRB2 (0.64) | PTPN1GRB2ITGB3ITGA2BALPI | |
| SCHEMBL4318313 | 0.77 | ALDH1A1 (0.54) | SCN9AALDH1A1MAPTATMFPR2 | |
| SCHEMBL8574571 | 0.77 | SCN9A (0.49) | SCN9AALDH1A1MAPTATMP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288549-B2 | Glycine B antagonist | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20110190342-A1 | GLYCINE B ANTAGONIST | HENRICH MARKUS | 2011-08-04 | — | — | US | disclosed |
| EP-2350014-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010037533-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA (DE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190342-A1 | GLYCINE B ANTAGONIST | GRIN2B, GLRB, GRIN2A | PTPN1 3936/4885SCN9A 1262/4885ALDH1A1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.